Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success

Beam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA application as early as this year.